|

|
|
|
Korea |
Korea's Dx&Vx signs $220 M agreement for mRNA cancer vaccine development with US biotech firm |

South Korea-based Dx&Vx (DXVX) has signed its first-ever global out-licensing agreement since its establishment. DXV...Read more
- 30 July 2025 News
|
|
Japan |
Viridian Therapeutics and Kissei Pharma ink deal worth $315 M focusing on thyroid eye disease in Japan |

Viridian Therapeutics, Inc., a US-based biopharmaceutical company focused on discovering, developing, and commercialisin...Read more
- 30 July 2025 News
|
|
|
|
|
China |
Dr. Falk Pharma and Allianthera (Suzhou) Biopharma to develop treatment for Ulcerative Colitis |

|
Dr. Falk Pharma GmbH, a Germany-headquartered research-based pharmaceutical company specialising in digestive and metabo...Read more
- 30 July 2025 News
|
|
Singapore |
Quasar Medical unveils new global headquarters in Singapore |

|
Quasar Medical, a global leader in manufacturing interventional and minimally invasive medical devices, has announced th...Read more
- 30 July 2025 News
|
|
|
|
|
Middle East countries |
IVI RMA Global expands footprint in reproductive medicine with acquisition of ART Fertility Clinics in UAE and Saudi Arabia |

|
Spain-based IVI RMA Global, the world-leading platform for reproductive medicine, has announced the acquisition of ART F...Read more
- 30 July 2025 News
|
|
|
|
|
All you want to read on
|

|
|
This email has been sent to you in association with
www.biospectrumasia.com
Tell Us What You Think! Help us improve our newsletters. Send us your feedback!
© Copyright 2025 MM ACTIV. All rights reserved.
To Unsubscribe click here.
Disclaimer : Please remember – by opting-in you are still able to opt-out at any time, by simply replying to this email at digital@mmactiv.com and typing 'unsubscribe' in the 'subject' field of any future emails. We promise only to send emails that we believe you will find interesting, relevant and current. Your data will never be sold or shared with any third party, although we may communicate a message to you from a partner that we are in collaboration with.
|
|
|